LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009, at 9:30am ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be accessed at www.biospecifics.com ("Future Company Presentation March 17, 2009"). The presentation will be archived for 90 days.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has filed a Biologic License Application with the U.S. Food and Drug Administration to market injectable collagenase (XIAFLEX(TM)) in the U.S. for the treatment of Dupuytren's disease, while Pfizer, Inc. is responsible for commercialization of XIAFLEX(TM) in Europe and other territories.
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2009 PR Newswire.
All rights reserved